Shanghai Qifuqing Material Technology Co., Ltd.

What they make

1 input Shanghai Qifuqing Material Technology Co., Ltd. supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Did you know2022

  PVP is a critical pore-forming additive in the manufacture of hollow fiber membranes used in water filtration, dialysis, and gas separation. Ultrafiltration (UF) and microfiltration (MF) membranes for water purification, kidney dialysis cartridges, and virus filtration in biopharmaceutical manufacturing are produced by phase-inversion casting of polymer solutions containing PVP as a pore-forming agent — the PVP leaches out during membrane formation, leaving controlled porosity. Shanghai Qifuqing's PVP is simultaneously a pharmaceutical tablet binder and the pore-forming agent in the membrane that cleans dialysis patients' blood and in the filtration membranes purifying drinking water in municipal water treatment plants. A PVP supply disruption would affect pharmaceutical manufacturing, kidney dialysis machine supply chain, and the water purification membranes serving municipal water infrastructure — through a single polymer's role as a pore-former across industries.

  Science Direct ↗

• Origin2011

  Polyvinylpyrrolidone (PVP) was invented in 1939 by Walter Reppe at BASF in Germany. During World War II, BASF developed injectable PVP (branded Periston) as a synthetic blood plasma substitute for German military wounded on the Eastern Front — where plasma supplies from blood donations could not keep pace with battlefield casualties. PVP dissolved in saline could be administered IV as a temporary plasma volume expander, buying time for blood transfusion. After WWII, the Allies captured the BASF PVP patents (part of German chemical IP seized under war reparations) and American pharmaceutical companies including ISP (International Specialty Products, formerly GAF) commercialized PVP for pharmaceutical tablets and personal care. Chinese producers including Shanghai Qifuqing entered the market decades later through reverse-engineering and scale-up, eventually capturing majority global market share. A molecule invented to keep Nazi soldiers alive on the Eastern Front is now manufactured in Shanghai and used to hold aspirin tablets together.

  Journal of Controlled Release ↗

• Concentration2023

  The global pharmaceutical-grade PVP market is now majority Chinese: Hangzhou Motto (~18%), Boai NKY (~20%), Shanghai Qifuqing (~14%) collectively control approximately 50%+ of global PVP supply, with BASF (Kollidon, ~25%) as the primary non-Chinese producer. The US has no significant PVP manufacturing capacity — ISP (previously the US domestic PVP producer) was acquired and largely shifted production. This concentration creates a single-country supply risk for a non-substitutable pharmaceutical excipient. Unlike APIs (active pharmaceutical ingredients) where US-China supply risk has been widely publicized and partially reshored, pharmaceutical excipient supply chain concentration has received far less regulatory attention — despite the fact that excipient unavailability is equally capable of shutting down drug manufacturing as API unavailability. [verify: China-majority PVP, BASF main Western; named producers real, %s single-source]

  U.S. Food and Drug Administration ↗